No business profile yet.
Size Applied Nutrition (APN.L) is a United Kingdom Health Care company (Pharmaceuticals: Other) with a market value of $986M, the 215th largest of 355 United Kingdom companies the cockpit tracks. Shares closed at £300.00 on 18 Nov 2026.
Performance Over six months the shares gained 31.0%, against -17.5% for the median peer and +0.1% for the United Kingdom market (cap-weighted) — 3rd highest of 21 in its peer set.
Growth Revenue grew 50.9% over the last twelve months (peer median +4.8%); the operating margin is 25.1% (peer median 14.0%).
Valuation It trades at 21.4× forward earnings against a peer median of 18.1× (7th most expensive of 17).
Price implies For today's price to make sense, revenue must grow about 25% a year for seven years (Req g). Recent delivered growth is +39%, so the hurdle is -14 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 25.9 points above its cost of capital (15.5% WACC).
Next results Next results expected around 12 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|---|
| Revenue | £162M | £162M | £107M | £86.2M | £60.8M |
| Revenue growth | — | +51% | +24% | +42% | — |
| Gross profit | £69.6M | £69.6M | £48.2M | £40.4M | £26.5M |
| EBITDA | £42.3M | £42.3M | £30.9M | £25.8M | £18.5M |
| Net income | £30.6M | £30.6M | £21.1M | £18.7M | £13.8M |
| Free cash flow | £10.6M | £10.6M | £15.2M | £6.28M | £7.62M |
| Capital expenditure | £2.00M | £2.00M | £1.00M | £1.06M | £1.00M |
| Total debt | n/a | £4.00M | £3.00M | £1.80M | £2.06M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | APN.L | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +3.6% | -7.3% | 4th highest of 21 |
| 6-month return | +31.0% | -17.5% | 3rd highest of 21 |
| Distance from 52-week high | -15.7% | -37.3% | 5th highest of 21 |
| Revenue growth (TTM) | +50.9% | +4.8% | 3rd highest of 21 |
| Operating margin | 25.1% | 14.0% | 4th highest of 21 |
| Forward P/E | 21.4× | 18.1× | 7th most expensive of 17 |
| Growth the price implies (Req g, 7 yrs) | 24.6% | 4.0% | most demanding of 16 |
| Growth delivered (Del g) | +38.5% | +13.5% | 3rd highest of 16 |
| Hurdle (Req g minus delivered) | -13.9 pp | -8.0 pp | 5th least demanding of 16 |
| ROIC minus cost of capital | +25.9 pp | +1.5 pp | 5th highest of 21 |
| EV / EBITDA | 17.4× | 18.9× | 5th cheapest of 10 |
| Net debt / EBITDA | -0.3× | -1.5× | 5th most indebted of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Applied Nutrition APN.L | United Kingdom | $986M | +31% | +51% | 25% | 21.4× | 24.6% | +38.5% |
| Shandong Xinhua Pharmaceutical 000756.SZ | China | $1.01B | -17% | -5% | 4% | 20.0× | 0.5% | +7.9% |
| New Journey Health Technology Group Co., Ltd.Class A 002219.SZ | China | $942M | -18% | -14% | 8% | 182.0× | n/a | n/a |
| Guilin Sanjin Pharmaceutical 002275.SZ | China | $1.05B | -12% | -3% | 24% | 12.8× | -8.7% | +5.5% |
| PharmaNutra PHN.MI | Italy | $922M | +2% | +17% | 22% | 33.5× | 4.7% | +18.5% |
| HBM 2142.HK | Hong Kong | $1.12B | -18% | +55% | 44% | 11.7× | 13.1% | +62.3% |
| Sihuan Pharmaceutical 0460.HK | Hong Kong | $856M | -34% | +30% | 15% | 8.7× | n/a | n/a |
| TSI 603262.SS | China | $842M | -46% | +3% | 14% | 47.7× | 24.3% | +13.4% |
| Cronos CRON.TO | Canada | $1.17B | +24% | +55% | 5% | 16.2× | 18.8% | +26.7% |
| Pharma Mar PHM.MC | Spain | $1.21B | -38% | +32% | 19% | 41.4× | 10.6% | -3.9% |
| BioGaia BIOG-B.ST | Sweden | $1.25B | -4% | +13% | 28% | 31.0× | 1.5% | +15.5% |
| Bora Pharmaceuticals 6472.TW | Taiwan | $1.25B | -2% | +7% | 14% | 10.8× | 3.5% | +60.2% |
| China Shineway Pharmaceutical 2877.HK | Hong Kong | $760M | -8% | -18% | 25% | 7.6× | n/a | n/a |
| Sirio Pharma 300791.SZ | China | $759M | -6% | -9% | 1% | 16.2× | 14.1% | +15.6% |
| Jamieson Wellness JWEL.TO | Canada | $1.32B | +32% | +12% | 13% | 20.6× | 13.5% | +15.3% |
| Tianjin Tianyao Pharmaceuticals 600488.SS | China | $718M | -36% | -12% | 3% | n/a | 2.1% | -1.3% |
| Shanghai Kaibao Pharmaceutical 300039.SZ | China | $703M | -20% | -14% | 22% | n/a | 0.4% | +4.8% |
| Sudeep Pharma SUDEEPPHRM.NS | India | $1.45B | +85% | +27% | 33% | 69.1× | n/a | n/a |
| Brother Enterprises 002562.SZ | China | $668M | -33% | +8% | 4% | n/a | 4.0% | +13.5% |
| Zhejiang Medicine 600216.SS | China | $1.51B | -26% | -6% | 7% | 11.5× | -7.8% | +3.9% |
| Shanxi Zhendong Pharmaceutical 300158.SZ | China | $641M | -22% | -28% | -25% | n/a | n/a | n/a |